

spiral structure to an elongated filament) so it is exposed to protease ADAMTS13 activity and triggers proteolysis, which reduces the number of high molecular weight (HMW) vWF multimers. HMW vWF multimers are important for haemostasis; they mediate platelet aggregation and adhesion to the subendothelium of the damaged blood vessels and in situations of high-speed blood flow. The angiodyplastic vessels themselves are associated with high-speed blood flow. In the absence of these multimers, prolonged bleeding would be expected.<sup>2-4,8</sup>

Endoscopic treatments, embolisation, surgery, hormone therapy or octreotide only elicit short-term success.<sup>8</sup> Stenotic valve replacement is the most effective treatment, as it corrects the blood supply to the intestine and the decreased HMW vWF multimers.<sup>2-4,8</sup> A review of the Mayo Clinic<sup>9</sup> presented 57 cases of Heyde syndrome treated with AVR, with a follow-up of 15 years. 79% of patients had no recurrence of bleeding, with a bioprosthesis as the valve of choice. King et al.<sup>10</sup> observed a decrease in gastrointestinal bleeding after AVR in 93% of patients.

In patients with AS who develop anaemia due to gastrointestinal bleeding, as well as assessing the most common causes (ulcers, neoplasms, ischaemic colitis, etc.), the possibility of HS should be considered. In patients presenting with gastrointestinal bleeding of unknown cause, AS must be ruled out. The most effective treatment for complete resolution of the symptoms is AVR.

#### REFERENCES

1. Heyde EC. Gastrointestinal bleeding in aortic stenosis. *N Engl J Med.* 1958;259:196.
2. Taguchi T, Watanabe M, Watadani K, Katayama K, Takahashi S, Takasaki T, et al. A case of Heyde syndrome: resolution following aortic valve replacement. *Heart Surg Forum.* 2014;17:E258-60.

3. Massyn MW, Khan SA. Heyde syndrome: a common diagnosis in older patients with severe aortic stenosis. *Age Ageing.* 2009;38:267-70.
4. Maor NR. Heyde syndrome: resolution of anemia after aortic valve surgery. *Isr Med Assoc J.* 2013;15:387-9.
5. Galanopoulos G. Angiodysplastic lesions as a cause of colonic bleeding in patients with chronic renal disease: is there an association? *Saudi J Kidney Dis Transpl.* 2012;23:925-8.
6. Pate GE, Chandavimol M, Naiman SC, Webb JG. Heyde's syndrome: a review. *J Heart Valve Dis.* 2004;13:701-12.
7. Shoenfeld Y, Eldar M, Bedazovsky B, Levy MJ, Pinkhas J. Aortic stenosis associated with gastrointestinal bleeding. A survey of 612 patients. *Am Heart J.* 1980;100:179-82.
8. İlkel E, Albeyoğlu Ş, Çiloğlu U, Sabri D. Heyde's syndrome. *Asian Cardiovasc Thorac Ann.* 2014;22:592-4.
9. Thompson JL 3rd, Schaff HV, Dearani JA, Park SJ, Sundt TM 3rd, Suri RM, et al. Risk of recurrent gastrointestinal bleeding after aortic valve replacement in patients with Heyde syndrome. *J Thorac Cardiovasc Surg.* 2012;144:112-26.
10. King RM, Pluth JR, Giuliani ER. The association of unexplained gastrointestinal bleeding with calcific aortic stenosis. *Ann Thorac Surg.* 1987;44:514-6.

Mónica Milla\*, Eduardo Hernández, Evangelina Mérida, Claudia Yuste, Paola Rodríguez, Manuel Praga

*Servicio de Nefrología, Hospital Universitario 12 de Octubre, Madrid, Spain*

\*Corresponding author.

E-mail address: [monica.milla15@gmail.com](mailto:monica.milla15@gmail.com) (M. Milla).

2013-2514/© 2017 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>). <https://doi.org/10.1016/j.nefro.2017.05.014>

## Hypotension in hemodialysis secondary to a reaction to synthetic membranes<sup>☆</sup>

### Hipotensión en hemodiálisis secundario a una reacción a membranas sintéticas

Dear Editor,

We present the case of an 84-year-old female patient on haemodialysis with a history of diabetes mellitus, arterial hypertension, dyslipidaemia, uric gout, two-vessel coro-

nary artery disease (AD/RC), apical necrosis, severe LV dysfunction and moderate aortic stenosis. She receives treatment with insulin, furosemide, sevelamer, atorvastatin, carvedilol, weekly IV iron sucrose and darbepoetin alpha 30 µg weekly. She is dialysed through a left internal radiocephalic

DOI of original article:

<http://dx.doi.org/10.1016/j.nefro.2017.04.001>.

☆ Please cite this article as: Delgado Córdova M, Blanco N, Azaña C. Hipotensión en hemodiálisis secundario a una reacción a membranas sintéticas. *Nefrología.* 2018;38:329-330.

arteriovenous fistula, with ultra-pure dialysis fluid using a Helixona® FX-80 dialyser (polysulfone).

The patient developed episodes of hypotension and precordial pain intradialysis. After being assessed by cardiology, heart surgery is ruled out because of an increased cardiovascular risk based on her age and associated comorbidities, as is percutaneous treatment because of the unfavourable coronary anatomy. In the sessions, she usually presents with hypotension 15–20 minutes after the start, sometimes with dyspnoea and chest tightness. ECG with no signs of acute ischaemia and normal cardiac enzymes, with slow recovery after infusion of saline solution, ending the session with normal blood pressure. Sessions of dialysis are scheduled with oxygen therapy, low hourly ultrafiltration rate, UF profiles and decreased bath temperature, with no improvement. After changing to another polymethylmethacrylate membrane (PMMA) dialyser, BG 2.1 U®, the patient starts to tolerate better the hemodialysis sessions. Since subsequently changing to a cellulose triacetate membrane, she has not presented with any further hypotensive episodes. In tests, she also had moderate eosinophilia and thrombocytopenia, which disappeared with the change of membrane.

Because of the patient's history, the intradialysis hypotensive episodes were first interpreted to be of cardiac origin, but as the change of membrane led to their complete disappearance, they were subsequently attributed to a reaction to the synthetic membrane. There was no history of allergies or eosinophilia, and other causes of hypersensitivity in dialysis such as the presence of endotoxins or other dialysis fluid pollutants,<sup>1</sup> ethylene oxide (EtO) as a sterilising agent (polysulfone is sterilised with steam and PMMA with gamma radiation),<sup>2</sup> iron allergy,<sup>3</sup> heparin<sup>4</sup> (anti-heparin antibodies negative) or latex<sup>5</sup> were ruled out.

This type of reaction to synthetic membranes may go unnoticed or be attributed to something else. They tend not to manifest at the initiation of the hemodialysis session. They are caused by pulmonary leukostasis secondary to complement activation by the dialysis membrane. The complement fraction C5a binds to the leucocyte receptors, eliciting their activation, aggregation and fixation to the pulmonary capillary endothelium, giving rise to leukopenia and hypoxaemia. The low leucocyte count gradually increases, reaching pre-session levels after an hour. The reaction resolves itself as the session goes on.<sup>6,7</sup> Cases of hypersensitivity reactions have been reported with the use of synthetic membranes, the majority due to polysulfone membranes, which contain an allergenic product, polyvinylpyrrolidone (PVP), used to hydrophilise the membrane. The PMMA membrane caused less complement activation and in this case, as with cellulose triacetate, it resolved the clinical symptoms.

A worsening of thrombocytopenia has been reported with some dialysers, with a much higher platelet count recorded in PVP-free dialysers than in membranes containing PVP.<sup>8</sup> Some cases of thrombocytopenia associated with respiratory symptoms have been reported, attributed to hypersensitivity to the dialyser<sup>9,10</sup>; those occurring in 2009/2010 were associated with sterilisation of the dialyser with gamma radiation.<sup>11</sup>

This case shows a reaction to polysulfone synthetic membrane, which manifests as hypotension and poor tolerance to

haemodialysis in a heart disease patient and which disappears after switching to PMMA and cellulose triacetate membranes. The classification of type A and B hypersensitivity reactions is very wide-ranging and not very useful here because the majority are not hypersensitivity reactions. Of more use clinically is a causal classification which includes; early reactions due to complement activation; reactions to EtO, reactions to pyrogens, reactions to AN-69, reactions to drugs used in haemodialysis and reactions to synthetic membranes.

## REFERENCES

1. Bigazzi R, Atti M, Baldari G. High-permeable membranes and hypersensitivity-like reactions: role of dialysis fluid contamination. *Blood Purif.* 1990;8:190–8.
2. Ebo DG, Bosmans JL, Couttenye MM, Stevens WJ. Haemodialysis-associated anaphylactic and anaphylactoid reaction. *Allergy.* 2006;61:211–20.
3. Rivera RF, Guido D, del Vecchio L, Corghi E, D'Amico M. Impact of European medicines agency recommendations for hypersensitivity reactions on intravenous iron prescription in haemodialysis centres of the Lombardy region. *J Nephrol.* 2016;29:673–81.
4. Berkun Y, Haviv YS, Schwartz LB, Shalit M. Heparin-induced recurrent anaphylaxis. *Clin Exp Allergy.* 2004;34:1916–8.
5. Kose S, Tatar B, Atalay S, Erden M, Tatar E. Latex-related allergy in hemodialysis patients. *Renal Fail.* 2013;35:888–90.
6. Alvarez-de Lara MA, Martín-Malo A. Hypersensitivity reactions to synthetic haemodialysis membranes – an emerging issue? *Nefrologia.* 2014;34:698–702.
7. Sánchez-Villanueva RJ, González E, Quirce S, Díaz R, Alvarez L, Menéndez D, et al. Hypersensitivity reactions to synthetic haemodialysis membranes. *Nefrologia.* 2014;34:520–5.
8. Hoenich NA, Katopodis KP. Clinical characterization of a new polymeric membrane for use in renal replacement therapy. *Biomaterials.* 2002;23:3853–8.
9. Posadas MA, Hahn D, Schleuter W, Paparello J. Thrombocytopenia associated with dialysis treatments. *Hemodial Int.* 2011;15:416–23.
10. Yang RC, Lindsay RM. Dialyzer reactions in a patient switching from peritoneal dialysis to hemodialysis. *Hemodial Int.* 2005;9:120–6.
11. Daugirdas JT, Bernardo AA. Hemodialysis effect on platelet count and function and hemodialysis-associated thrombocytopenia. *Kidney Int.* 2012;82:147–57.

Margarita Delgado Córdova\*, Natalia Blanco, Claudia Azaña

*Servicio de Nefrología, Hospital Quirónsalud A Coruña, A Coruña, Spain*

\* Corresponding author.

E-mail address: [margaritadelcor@yahoo.es](mailto:margaritadelcor@yahoo.es)  
(M. Delgado Córdova).

2013-2514/© 2017 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).  
<https://doi.org/10.1016/j.nefro.2017.04.019>